INTRODUCTION:Noninvasive pressure support ventilation (NIPSV) and continuous positive airway pressure (CPAP) are both advocated in the treatment of cardiogenic pulmonary edema (CPE); however, the superiority of one technique over the other has not been clearly demonstrated. With regard to its physiological effects, we hypothesized that NIPSV would be better than CPAP in terms of clinical benefit. METHODS: In a prospective, randomized, controlled study performed in four emergency departments, 200 patients were assigned toCPAP (n = 101) or NIPSV (n = 99). Primary outcome was combined events of hospital death and tracheal intubation. Secondary outcomes included resolution time, myocardial infarction rate, and length of hospital stay. Separate analysis was performed in patients with hypercapnia and those with high B-type natriuretic peptide (>500 pg/ml). RESULTS:Hospital death occurred in 5 (5.0%) patients receiving NIPSV and 3 (2.9%) patients receiving CPAP (p = 0.56). The need for intubation was observed in 6 (6%) patients in the NIPSV group and 4 (3.9%) patients in the CPAP group (p = 0.46). Combined events were similar in both groups. NIPSV was associated to a shorter resolution time compared to CPAP (159 ± 54 vs. 210 ± 73 min; p < 0.01), whereas the incidence of new myocardial infarction was not different between both groups. Similar results were found in hypercapnic patients and those with high B-type natriuretic peptide. CONCLUSIONS: During CPE, NIPSV accelerates the improvement of respiratory failure compared to CPAP but does not affect primary clinical outcome either in overall population or in subgroups of patients with hypercapnia or those with high B-type natriuretic peptide.
RCT Entities:
INTRODUCTION: Noninvasive pressure support ventilation (NIPSV) and continuous positive airway pressure (CPAP) are both advocated in the treatment of cardiogenic pulmonary edema (CPE); however, the superiority of one technique over the other has not been clearly demonstrated. With regard to its physiological effects, we hypothesized that NIPSV would be better than CPAP in terms of clinical benefit. METHODS: In a prospective, randomized, controlled study performed in four emergency departments, 200 patients were assigned to CPAP (n = 101) or NIPSV (n = 99). Primary outcome was combined events of hospital death and tracheal intubation. Secondary outcomes included resolution time, myocardial infarction rate, and length of hospital stay. Separate analysis was performed in patients with hypercapnia and those with high B-type natriuretic peptide (>500 pg/ml). RESULTS: Hospital death occurred in 5 (5.0%) patients receiving NIPSV and 3 (2.9%) patients receiving CPAP (p = 0.56). The need for intubation was observed in 6 (6%) patients in the NIPSV group and 4 (3.9%) patients in the CPAP group (p = 0.46). Combined events were similar in both groups. NIPSV was associated to a shorter resolution time compared to CPAP (159 ± 54 vs. 210 ± 73 min; p < 0.01), whereas the incidence of new myocardial infarction was not different between both groups. Similar results were found in hypercapnic patients and those with high B-type natriuretic peptide. CONCLUSIONS: During CPE, NIPSV accelerates the improvement of respiratory failure compared to CPAP but does not affect primary clinical outcome either in overall population or in subgroups of patients with hypercapnia or those with high B-type natriuretic peptide.
Authors: J Masip; A J Betbesé; J Páez; F Vecilla; R Cañizares; J Padró; M A Paz; J de Otero; J Ballús Journal: Lancet Date: 2000 Dec 23-30 Impact factor: 79.321
Authors: John Victor Peter; John L Moran; Jennie Phillips-Hughes; Petra Graham; Andrew D Bersten Journal: Lancet Date: 2006-04-08 Impact factor: 79.321
Authors: Andrea Bellone; Marco Vettorello; Alessandra Monari; Francesca Cortellaro; Daniele Coen Journal: Intensive Care Med Date: 2005-05-04 Impact factor: 17.440
Authors: Josep Masip; W Frank Peacock; Susanna Price; Louise Cullen; F Javier Martin-Sanchez; Petar Seferovic; Alan S Maisel; Oscar Miro; Gerasimos Filippatos; Christiaan Vrints; Michael Christ; Martin Cowie; Elke Platz; John McMurray; Salvatore DiSomma; Uwe Zeymer; Hector Bueno; Chris P Gale; Maddalena Lettino; Mucio Tavares; Frank Ruschitzka; Alexandre Mebazaa; Veli-Pekka Harjola; Christian Mueller Journal: Eur Heart J Date: 2018-01-01 Impact factor: 29.983
Authors: Massimo Antonelli; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; J Randall Curtis; Daniel De Backer; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Patricia Rocco; Jean-François Timsit; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2012-02-14 Impact factor: 17.440
Authors: Damien Contou; Chiara Fragnoli; Ana Córdoba-Izquierdo; Florence Boissier; Christian Brun-Buisson; Arnaud W Thille Journal: Ann Intensive Care Date: 2015-06-07 Impact factor: 6.925